Summary

US Cardiac Rhythm Management Devices Market is valued approximately USD 4.64 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.46% over the forecast period 2024-2032. Cardiac rhythm management (CRM) devices are advanced medical tools designed for monitoring and regulating the electrical functions of the heart. They are particularly utilized in patients experiencing heart rhythm irregularities such as arrhythmias, bradycardia (slow heart rate), and tachycardia (rapid heart rate). CRM devices encompass various technologies, including implanted cardioverter defibrillators (ICDs), crucial for addressing life-threatening arrhythmias; pacemakers, which sustain a regular heart rhythm by delivering controlled electrical impulses; and cardiac resynchronization therapy (CRT) devices, which optimize heart performance in individuals with heart failure. These devices are essential for improving patients' quality of life and controlling cardiac diseases. The rising shift towards personalized and precision medicine is a key trend that is supporting the growth of the US Cardiac Rhythm Management Devices Market.

An increased emphasis has been placed on customizing therapies to meet the needs of each patient as a result of technological and medical breakthroughs. This trend has resulted in the development of sophisticated software and algorithms that maximize the programming and operation of cardiac rhythm management devices, including cardiac resynchronization treatment (CRT) devices, pacemakers, and implanted cardioverter defibrillators (ICDs). Key factors such as the presence of well-established healthcare infrastructure, government support, and the increasing prevalence of cardiovascular diseases necessitating greater use of cardiac implants. Factors such as elevated rates of obesity, smoking, and unhealthy lifestyles contribute to a higher risk of heart-related ailments like heart attacks, further boosting the demand for cardiac rhythm management devices in the region. Additionally, the rigorous enforcement of government regulations regarding the installation of external defibrillators in public areas is expected to drive higher adoption rates of these devices leading to a subsequent market boost for external defibrillators, which is contributing to the regional market growth. However, stringent regulatory approvals, along with side effects of therapeutic radiation on implantable cardiac rhythm devices is expected to hinder the US Cardiac Rhythm Management Devices market growth during the estimated period of 2024-2032.


Major market player included in this report are:
Physio-Control, Inc.
Abbott Laboratories
Boston Scientific Corporation
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10



The detailed segments and sub-segment of the market are explained below:

By Product
Pacemakers
Defibrillators
Cardiac Resynchronization Therapy (CRT))

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. US Cardiac Rhythm Management Devices Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Cardiac Rhythm Management Devices Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Product
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Cardiac Rhythm Management Devices Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Cardiac Rhythm Management Devices Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Cardiac Rhythm Management Devices Market Size & Forecasts by Product 2022-2032
5.1. Pacemakers
5.2. Defibrillators
5.3. Cardiac Resynchronization Therapy (CRT))
Chapter 6. Competitive Intelligence
6.1. Key Company SWOT Analysis
6.1.1. Company 1
6.1.2. Company 2
6.1.3. Company 3
6.2. Top Market Strategies
6.3. Company Profiles
6.3.1. Physio-Control, Inc.
6.3.1.1. Key Information
6.3.1.2. Overview
6.3.1.3. Financial (Subject to Data Availability)
6.3.1.4. Product Summary
6.3.1.5. Market Strategies
6.3.2. Abbott Laboratories
6.3.3. Boston Scientific Corporation
6.3.4. Company 4
6.3.5. Company 5
6.3.6. Company 6
6.3.7. Company 7
6.3.8. Company 8
6.3.9. Company 9
6.3.10. Company 10
Chapter 7. Research Process
7.1. Research Process
7.1.1. Data Mining
7.1.2. Analysis
7.1.3. Market Estimation
7.1.4. Validation
7.1.5. Publishing
7.2. Research Attributes